Gender Diversity in Indian Pharma
India could boost its GDP by USD 0.7 trillion in 2025 by matching the rate of improvement of gender equality of the leading country in its region. Despite the prevalence…
Address: First Floor, Su Motor Complex,, Veena Nagar, Mulund West, Mumbai-400 080,India
Tel: 022 30781000
Web: http://truecare.in/Truecare/
Abbott is a diverse global health care company with scientific expertise and products that address the varied healthcare needs of the people.
Abbott has been present in India for over 100 years now starting operations in 1910. The company’s pharmaceutical offerings expanded significantly over the years through organic growth and acquisitions. Currently Abbott is India’s largest pharmaceutical company in 2010 with the acquisition of Knoll, Solvay pharmaceuticals and Piramal Healthcare (domestic formulations division)
The product portfolio in India can be categorized into three broad categories – Pharmaceuticals, Nutrition and Medical devices.
Abbott serves the evolving healthcare needs of Indian consumers by introducing products backed by strong R&D. In addition our Established Pharmaceuticals Division (EPD) offers an expanding portfolio of branded generic drugs.
Our global citizenship priorities address the principal economic, social and environmental challenges necessary for a healthy society and a favorable business environment.
With over 13,000 people, India is Abbott’s largest employee base outside the United States. The company seeks to attract, retain and develop the best talent to ensure a healthy, safe, fulfilling work environment for all employees in India.
The product portfolio in India can be categorized into three broad categories – Pharmaceuticals, Nutrition and Medical devices.
Abbott serves the evolving healthcare needs of Indian consumers by introducing products backed by strong R&D. In addition our Established Pharmaceuticals Division (EPD) offers an expanding portfolio of branded generic drugs.
Our global citizenship priorities address the principal economic, social and environmental challenges necessary for a healthy society and a favorable business environment.
India could boost its GDP by USD 0.7 trillion in 2025 by matching the rate of improvement of gender equality of the leading country in its region. Despite the prevalence…
As a young pathbreaking transformer in the Indian pharmaceutical landscape, Yogesh Agrawal, managing director of Ajanta Pharma Ltd., shares his desire to accelerate the company’s expansion in the US. Out…
Sanjay Bhutani, managing director of Bausch & Lomb India and SAARC operations, gives his insights into the thriving visual care industry which has allowed the company to launch 31 intraocular…
At the Organization of Pharmaceuticals Producers of India (OPPI), the association representing the research-based pharmaceutical companies in India, putting the patient at the center of all that they do is…
Bhupendra Singh, chairman of the Indian National Pharmaceutical Pricing Authority (NPPA), provides an overview of the current mechanisms governing the pharmaceutical and life sciences industry in India, highlighting the challenges…
Sir Dr. Huz, CEO and trustee of the Wockhardt Foundation and executive director of Wockhardt, discusses the role the Foundation plays in low- and middle-income areas across India, and how integrating simple…
The secretary-general of the Indian Drug Manufacturers Association (IDMA) gives his insight into the current state of the Indian pharma industry, the IDMA’s role in raising the quality of Indian-made…
The Indian joint secretary for commerce and industry, interviewed at CPhI Worldwide 2014 in Paris, discusses India’s place in the global pharmaceutical landscape, and emphasizes the country’s contribution to the…
You have only recently been appointed Managing Director for the first time in your career. How did your first year with UCB India go so far? My first year at…
TCS Life Sciences and Healthcare vertical was created within the Tata Group 10 years ago. Can you explain to the readers, how such a diversified group such as Tata decided…
Novo Nordisk seems somewhat of an exception to the MNCs that recently entered India, as it already set up its HQ in Bangalore in 1994. How do you explain this…
The Indian biotechnology sector is quite particular. In spite of its young age, the industry has grown significantly in a very short time. In your view, where does the Indian…
See our Cookie Privacy Policy Here
